Option chain shows key data for California's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for California.

California (OTC:CANOF) Stock, Option Chain

California Nanotechnologies Corp engages in the production, and research and development of nanostructured components and materials. Its products include precision forged components, thermal spray powders, nano light alloy powders, nanoalloy billets, nano superalloy powders, cemented carbides, and tooling. The company products are used in Aerospace, Defense, Automotive, Medical, and Sport and Recreation industries. It has extensive experience in dozens of R&D and pilot production projects with Industrial partners, National Labs, and Universities.

CALIFORNIA NANOTECHS CORP by California Nanotechnologies Corp

California Nanotechnologies Corp

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $18 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

VNDA

HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.</p>


RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

Market-Moving Exclusives

Exclusives

TELO

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga Co. Confirms Copper-Binding Capabilities Of Telomir-1 And Expands Pipeline Into Wilson's Disease

<p>Castellum, Inc. (NYSE-American: CTM) ("Castellum"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its <a href="https://www.globenewswire.com/Tracker?data=2uLrI8261QtiQmeyEX_gy6JpQ-moKeUMas7MX0KiELEefnH75OHV-JXUfPsv_zKI7gHoXxkBqsvA_eImOxN3D6G4PL5vSPCM60jU0LeJn-vqxAiMc5Hvq23f7HgN9H_j">subsidiary Specialty Systems, Inc.,</a> teaming with Castellum's other two subsidiaries <a href="https://www.globenewswire.com/Tracker?data=xuSy8FtCDO83pGRtqv3Bvd1mPpu7go0e-GbTqJOQfJpOv_sGIz-OJqLYw2ishXp8SNb4c4XnqbhR6CDFldnrtW6jI5X0Ly8kGJnXmWf_r7srd0t2OloOpVJX64Fh8CLU">Corvus Consulting, LLC</a> and <a href="https://www.globenewswire.com/Tracker?data=k8X5vM0eJAl01EJ9rJycnEmDk9yQVQVWU5kbUoIek9XS_3bxyu5GYFX64I44ybWTUYMcTU2iovmCpcKa02R-MD1goOgkN92qMYL4z1wzHMwClXsrY-NBB5mNeW7suWDSQclfL1E3M0ECNAUCnxh1Kg==">Global Technology and Management Resources, Inc.,</a> was awarded all four unrestricted domains upon which it submitted proposals. This award is in addition to the three small business domains the Castellum team has already been awarded on One Acquisition Solution for Integrated Services Plus ("OASIS+").</p>
<p>OASIS+ is a suite of government-wide, multi-award contracts designed to support federal agencies' procurement requirements for services-based solutions. With a potential ten-year performance period and no ceiling value, OASIS+ represents a significant opportunity for the Castellum team to expand its support to federal customers.</p>


Government

Regulations

Castellum Secures Major Federal Contract Awards Through OASIS+ Program

GPUS

Hyperscale Data Secures Financing Agreement For Up To $25M In Series G Convertible Preferred Stock

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.</p>


RMTI

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

<p>On Monday, <strong>Telomir Pharmaceuticals, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.</p>
<p>Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.</p>
<p>According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.</p>
<p>Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.</p>
<p>Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.</p>
<p>The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.</p>
<p>In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.</p>
<p>"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."</p>
<p><strong>Price Action:</strong> TELO shares closed 14.10% higher at $5.18 on Friday.</p>


Biotech

Health Care

General

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54170253&amp;newsitemid=20241223250943&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=b5586a81e66ef03f03c233e8008cee0b">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the European Commission (EC) has approved <i>Opdivo&#xAE;</i> (nivolumab) plus <i>Yervoy&#xAE;</i> (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).</p>
<p>"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, <i>Opdivo</i> global program lead, Bristol Myers Squibb. "The EC's decision to approve <i>Opdivo </i>plus <i>Yervoy</i> represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."</p>


Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment

<p>DA Davidson  analyst Linda Bolton Weiser   maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.</p>


DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.</p>


BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

<p>HC Wainwright &amp; Co.  analyst Yi Chen   initiates coverage on Sanara MedTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTI#NASDAQ">SMTI</a>) with a Buy rating and announces Price Target of $50.</p>


Initiation

SMTI

HC Wainwright & Co. Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $50

<p>Telsey Advisory Group  analyst Joseph Feldman   maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $70 price target.</p>


Telsey Advisory Group Maintains Outperform on Kroger, Maintains $70 Price Target

<p>HC Wainwright &amp; Co.  analyst Andres Maldonado   initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $25.</p>


ENGN

HC Wainwright & Co. Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $25

<p>NanoViricides, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug.</p>
<p>"Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."</p>
<p>WHO has stated "Available virus sequences from human cases [of H5 infection] have shown some genetic markers that may reduce susceptibility to neuraminidase inhibitors (antiviral medicines such as oseltamivir) [NAIs] or endonuclease inhibitors (such as baloxavir marboxil) [PBIs]" in their updated public health assessment of recent Influenza A H5 infections, dated December 20, 2024</p>


NNVC

NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic

<p>Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) today announced it has agreed to acquire Lexmark International, Inc., from Ninestar Corporation, PAG Asia Capital, and Shanghai Shouda Investment Centre in a deal valued at $1.5 billion, inclusive of assumed liabilities. This acquisition will strengthen the Xerox core print portfolio and build a broader global print and managed print services business better suited to meet the evolving needs of clients in the hybrid workplace.</p>


Xerox to Acquire Lexmark in $1.5B Deal to Expand Print Services

<p>On December 20, 2024, Strawberry Fields REIT, Inc. (the "Company") entered into a Purchase and Sale Agreement with an unaffiliated seller with respect to six Healthcare Facilities located in Kansas (the "Facilities").
</p><p>On December 20, 2024, Strawberry Fields REIT, Inc. (the "Company") entered into a Purchase and Sale Agreement with an unaffiliated seller with respect to six Healthcare Facilities located in Kansas (the "Facilities"). The purchase price for the Facilities is $24,000,000, payable at the closing.</p>
<p>The six facilities are comprised of five skilled nursing facilities and one assisted living facility with 354 licensed beds.</p>
<p>The facilities will be leased to Advena Living led by its founder Willie Novotny. The lease is for an initial 10-year period and includes two 5-year tenant options on a triple-net basis. Additionally, the lease will increase the Company's annual rents by $2.4 million and is subject to 3% annual increases.</p>
<p>The Company plans to purchase the facilities utilizing the Company's current working capital.</p>


STRW

Strawberry Fields REIT To Acquire Six Kansas Healthcare Facilities for $24M

<p>Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.</p>
<p>Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy.</p>
<p>"It is estimated that 1 in 10 dogs will experience heart disease in their life and unfortunately, most go undetected," said Dr. Kelli Puccio, a Professional Services Veterinarian for Zomedica. "Diagnosing and evaluating cardiac disease in our canine patients can be challenging. The TRUFORMA canine NT-proBNP assay facilitates the early detection of canine heart disease with the convenience of results in just a few minutes. This provides veterinarians with the ability to start treatments and schedule advanced diagnostic tests more quickly. Increasing our patients' quality of life earlier in the disease process." Additionally, this assay runs on either plasma or serum allowing more flexibility within a clinic's natural workflow.</p>
<p><br />&nbsp;</p>


Zomedica Launches New Canine Tests for Faster Heart Disease Detection

<p>HC Wainwright &amp; Co.  analyst Scott Buck   maintains SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) with a Buy and raises the price target from $8 to $26.</p>


SOUN

HC Wainwright & Co. Maintains Buy on SoundHound AI, Raises Price Target to $26

<p><a href="https://www.globenewswire.com/Tracker?data=EvK5qYIL7c_16K93ZBIV_UFtMgPcLGgkcD7IshY3PCtSMlupDBlYnqtVSWF1N4Gw2XKatFqrvbqOxjYWR9wI5K4prfcV9UU3A5dR9pU3RKI=">Hyperscale Data, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>), a diversified holding company ("<strong>Hyperscale Data</strong>" or the "<strong>Company</strong>"), announced today that it has entered into a Securities Purchase Agreement (the "<strong>Agreement</strong>") providing for up to $25 million of financing (the "<strong>Financing</strong>") from Ault &amp; Company, Inc., a related party ("<strong>A&amp;C</strong>"). Pursuant to the Agreement, Hyperscale Data has agreed to issue and sell to A&amp;C up to $25 million in shares of Series G Convertible Preferred Stock (the "<strong>Preferred Shares</strong>"). The Preferred Shares will be senior to all other classes of preferred stock the Company has outstanding except with respect to the Series C Convertible Preferred Stock (the "<strong>Series C Preferred Stock</strong>"), with which it ranks in parity, as well as senior to the Company's Class A common stock ("<strong>Common Stock</strong>").</p>
<p>Each Preferred Share shall have a stated value of $1,000.00 per share and, upon stockholder approval, shall be convertible at the holder's option into shares of Common Stock at a conversion price equal to the greater of (i) $0.10 per share (the "<strong>Floor Price</strong>"), which Floor Price shall not, except for voting rights purposes, be adjusted for stock dividends, stock splits, stock combinations and other similar transactions and (ii) the lesser of (A) $6.74, or (B) a 5% premium to the closing sale price of the Common stock on the day immediately prior to the date of conversion (the "<strong>Conversion Price</strong>"). The Conversion Price will be subject to standard anti-dilution provisions in connection with any stock split, stock dividend, subdivision or similar reclassification of the Common Stock. The Preferred Stock also has "full ratchet" price protection in the event the Company should issue securities at a lower price than the Conversion Price. The Preferred Stock shall pay a dividend at an annual rate of 9.5%, which the Company may, during the first two years, pay in shares of Common Stock.</p>
<p>Further, A&amp;C will receive warrants ("<strong>Warrants</strong>") to purchase up to approximately 4.25 million shares of Common Stock, presuming that the full amount of the Preferred Shares is sold, exercisable for five years at $5.92 per share, subject to adjustment.</p>
<p>The proceeds from the Financing will be used for expansion of the MI data center to support infrastructure upgrades necessary to support the growing demands of high-performance computing services powering Artificial Intelligence solutions, repayment of outstanding indebtedness and general working capital purposes.</p>


Hyperscale Data Secures $25M Financing to Boost AI Infrastructure Expansion

<p>HC Wainwright &amp; Co.  analyst Scott Buck   maintains Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) with a Buy and raises the price target from $5 to $7.</p>


DPRO

HC Wainwright & Co. Maintains Buy on Draganfly, Raises Price Target to $7

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>There are ample opportunities among undiscovered <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> because there are two ways that shares can move higher. First, via price discovery. Undiscovered names, especially in the OTC market, can be undervalued and then re-rated as investors bid them up. Second, these small companies often see major improvements in performance. This, too, can be a major driver for outsized gains.</p>



<p><strong>Elite Pharmaceuticals</strong> was one of my undiscovered penny stocks sit. <a href="https://investorplace.com/2022/09/7-best-penny-stocks-for-10-cents-or-less/">In 2022</a>, it was around 3 cents per share, 6 times earnings. Today, it&rsquo;s 19 cents per share, 10.8 times earnings. So, what are some examples of high-potential undiscovered penny stocks right? Take a look at these seven. Each one could generate tremendous gains in the coming years.</p>



<h2>Butler National (BUKS)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/casino1600-300x169.jpg" alt="a room of slot machines in a casino to represent gambling stocks"><div>Source: Shutterstock</div></div>


<p><strong>Butler National</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/buks-stock-quote/"><strong>BUKS</strong></a>) is an obscure stock I&rsquo;ve discussed before in past coverage of penny stocks. While primarily an aerospace products and services company, Butler also owns a casino (Boot Hill) in Dodge City, Kansas.</p>



<p>As I argued last October, the primary appeal with BUKS stock is its <a href="https://investorplace.com/2023/10/these-7-penny-stocks-could-triple-your-investment-in-a-decade/">low valuation, coupled with recent developments that could help shake off its &ldquo;value trap&rdquo; status</a>. Shares are sold for just 7.7 times forward earnings. Stocks in both aerospace and gaming, which are comparable, trade at multiples of at least double this figure.</p>



<p>Even if the company does not get bought out, something else could serve as a catalyst. Last year&rsquo;s management changes are set to both reduce overhead expenses, and perhaps result in the company making other moves (such as a stock market up-listing, or a spin-off of the casino business) that may help Butler escape obscurity, and to unlock shareholder value.</p>



<h2>California Nanotechnologies (CANOF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-man-figurine-300x169.jpg" alt="penny stocks. Penny Stocks with Potential"><div>Source: Shutterstock</div></div>


<p><strong>California Nanotechnologies</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/canof-stock-quote/"><strong>CANOF</strong></a>), also known as Calnano, is a provider of nanocrystalline materials for R&amp;D and industrial use. The company&rsquo;s shares have taken off in the past year (rising by more than 160%), but price discovery may not be over just yet.</p>



<p>Despite the significant increase in CANOF stock, it still trades at a reasonable valuation (11.7 times earnings). More importantly, as seen in Calnano&rsquo;s recent investor presentation, expected growth for one of the company&rsquo;s key markets (<a href="https://www.calnanocorp.com/Cal-Nano-Q3-2024-Investor-Presentation.pdf">the spark plasma sintering market</a>), suggests that a high level of growth may continue.</p>



<p>With this, CANOF may be well-positioned to both rise in line with earnings growth, as well as experience an expansion of its earnings multiple. In time, Calnano (which also trades in Canada on the <strong>TSX Venture</strong> exchange) could decide to move its U.S. stock market listing from the OTC market, to a major exchange.</p>



<h2>Comstock Holding (CHCI)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/house-home-desert-housing-crisis-1600-300x169.jpg" alt="Flat cut-out image of house jammed into the crack of dry desert, symbolizing housing crisis"><div>Source: shutterstock.com/Roman Bodnarchuk</div></div>


<p>Investors looking to make a contrarian wager on commercial real estate have many choices, but one they may want to consider is <strong>Comstock Holding</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/chci-stock-quote/"><strong>CHCI</strong></a>). </p>



<p>Originally in the homebuilding business, in more recent years Comstock has become a commercial property management firm, managing primarily mixed-use developments in the Washington, D.C. metropolitan area.</p>



<p>CHCI stock has held steady, despite the continued worries about whether the commercial real estate market downturn will worsen or stabilize from here. This share price steadiness more than makes sense. Comstock&rsquo;s <a href="https://ir.comstock.com/news/news-details/2023/Comstock-Reports-Third-Quarter-2023-Results/default.aspx">revenue and earnings</a> keep growing, as seen from the company&rsquo;s Q3 2023 results.</p>



<p>Still, the market still seems to ignore this, assigning CHCI a valuation (6.7 times earnings) well below that of other publicly-traded property management companies (which trades for 10-15 times earnings). Greater awareness of Comstock, plus normalization of conditions in the commercial property space, could help to bridge this valuation gap.</p>



<h2>Greystone Logistics (GLGI)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/polypropylene-plastic-1600-300x169.jpg" alt="A photo of a pile of red polypropylene plastic pellets."><div>Source: Anastasiia Burlutskaia / Shutterstock.com</div></div>


<p><strong>Greystone Logistics</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/glgi-stock-quote/"><strong>GLGI</strong></a>) may be up by 150% over the past year, but it&rsquo;s arguably still one of the undiscovered penny stocks. At least, based on this plastic pallet manufacturer&rsquo;s current valuation. </p>



<p>Yes, it is misleading to use the company&rsquo;s trailing twelve month earnings to value the stock.</p>



<p>Greystone&rsquo;s earnings last year were skewed by a one-time event (<a href="https://compliance-sec.com/secfilings/company/glgi/link_files/2023/08-28-2023/Form10-K(08-28-2023)GreystoneLogistics/Form10-K.pdf">the receipt of a massive pandemic-related refundable tax credit</a>). However, based on more recent results, such as <a href="https://compliance-sec.com/secfilings/company/glgi/link_files/2024/01-16-2024/Form10-Q(01-16-2024)GreystoneLogistics/Form10-Q.pdf">earnings of 3 cents per share</a> last quarter, it&rsquo;s clear cooling inflation and rebounding demand are helping to improve margins.</p>



<p>If this keeps playing out, GLGI stock could rise, as it becomes clear that the company is once again consistently-profitable thanks to its operating business, not because of tax credits. This could result in a re-rating, enabling this already strong-performing penny stock to add to its gains.</p>



<h2>Mama&rsquo;s Creations (MAMA)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/food-packaging-1600-300x169.png" alt="A photo of various food packaging containers."><div>Source: Pixel-Shot / Shutterstock.com</div></div>


<p>Admittedly, it may be a stretch to call <strong>Mama&rsquo;s Creations</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mama-stock-quote/"><strong>MAMA</strong></a>) shares undiscovered. </p>



<p>In recent years, this purveyor of &ldquo;heat and serve&rdquo; foods has already experienced a high level of growth, as well as an outsized amount of price appreciation for its formerly OTC-listed, now NASDAQ-listed shares.</p>



<p>As recently as late 2022, MAMA stock traded for just over $1 per share. Today, it trades for $4.50 per share. Yet while the stock is up by a tremendous amount already, the potential is still there for shares to keep growing at a slower but still above-average pace.</p>



<p>Per sell-side forecasts, earnings could grow by as much as <a href="https://seekingalpha.com/symbol/MAMA/earnings">43.75%</a> this fiscal year (ending January 2025). While priced already like a growth stock at 26.7 times forward earnings, continued growth could help sustain this valuation, with shares moving higher in tandem with increased earnings.</p>



<h2>Power Solutions International (PSIX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/09/car_motor_1600-300x169.jpg" alt="A close-up photograph of a car engine representing SINT Stock."><div>Source: OlegRi / Shutterstock.com</div></div>


<p>If searching for deep value plays among undiscovered penny stocks, consider <strong>Power Solutions International</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/psix-stock-quote/"><strong>PSIX</strong></a>). Shares in this manufacturer of engines and power systems trade for only 2 times forward earnings.</p>



<p>Yes, there&rsquo;s somewhat of a rationale for the super-low valuation of PSIX stock. As InvestorPlace&rsquo;s Omor Ibne Ehsan discussed last November, Power Solutions International has <a href="https://investorplace.com/2023/11/buy-alert-analysts-say-these-3-growth-stocks-could-double-in-2024/">in the past been unprofitable</a>, reporting high levels of cash burn. This may mean investors are still skeptical about future operating performance.</p>



<p>Power Solutions could continue to handily beat expectations with subsequent quarterly results. Sell side forecasts call for earnings of <a href="https://seekingalpha.com/symbol/PSIX/earnings">$1.22</a> per share during 2024. This may only represent 14% earnings growth compared to 2023. </p>



<p>However, as this would also signal that the company has achieved consistent profitability, this may assuage investor concerns, resulting in (as Ehsan also argued previously), a major re-rating to the upside for shares.</p>



<h2>Vaso (VASO)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>


<p>At the same time I &ldquo;discovered&rdquo; ELTP, I also discovered medical technology company <strong>Vaso</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/vaso-stock-quote/"><strong>VASO</strong></a>). Since then, many other investors have discovered it as well. </p>



<p>This, plus enormous improvements in Vaso&rsquo;s profitability, have resulted in a high amount of price appreciation for shares.</p>



<p>Trading for just over a dime in 2022, VASO stock today trades for around 28 cents per share. However, even after this big run-up, don&rsquo;t assume you have missed the boat. In fact, Vaso could pretty soon become even more greatly followed by the market.</p>



<p>How? Back in December, the company announced <a href="https://www.prnewswire.com/news-releases/vaso-corporation-a-diversified-medical-technology-company-currently-trading-on-the-otcqx-market-to-list-on-nasdaq-via-spac-merger-302009376.html">plans to merge</a> with special purpose acquisition company (or SPAC) <strong>Achari Ventures Holdings Corp I</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/avhi-stock-quote/"><strong>AVHI</strong></a>). </p>



<p>Merging with Achari, in effect a market uplisting and reverse split, could bring about a fresh wave of price discovery. Trading for just 4 times earnings, shares could receive a big re-rating after the SPAC merger closes.</p>



<p><em>On the date of publication, Thomas Niel&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Thomas Niel, contributor for InvestorPlace.com, has been writing single-stock analysis for web-based publications since 2016.</p></div>	<div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/?p=2652004">7 Undiscovered Penny Stocks Poised for Meteoric Rises</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Comments

California

California (CANOF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga